DHRS1

Summary

DHRS1 (dehydrogenase/reductase 1, HGNC:16445) is a protein-coding gene on chromosome 14q12, encoding Dehydrogenase/reductase SDR family member 1 (Q96LJ7). NADPH-dependent oxidoreductase which catalyzes the reduction of steroids (estrone, androstene-3,17-dione and cortisone) as well as prostaglandin E1, isatin and xenobiotics in vitro.

This gene encodes a member of the short-chain dehydrogenases/reductases (SDR) family. The encoded enzyme contains a conserved catalytic domain and likely functions as an oxidoreductase. Multiple alternatively spliced variants, encoding the same protein, have been identified.

Source: NCBI Gene 115817 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 57 total
• MANE Select transcript: NM_001136050

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16445
Approved symbol	DHRS1
Name	dehydrogenase/reductase 1
Location	14q12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25430, MGC20204, SDR19C1
Ensembl gene	ENSG00000157379
Ensembl biotype	protein_coding
OMIM	610410
Entrez	115817

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 7 protein_coding, 6 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000288111, ENST00000396813, ENST00000558114, ENST00000558340, ENST00000559084, ENST00000559088, ENST00000559483, ENST00000560991, ENST00000561137, ENST00000561273, ENST00000561281, ENST00000860257, ENST00000860258, ENST00000860259, ENST00000941472, ENST00000941473

RefSeq mRNA: 2 — MANE Select: NM_001136050 NM_001136050, NM_138452

CCDS: CCDS9623

Canonical transcript exons

ENST00000288111 — 9 exons

Exon	Start	End
ENSE00001032196	24292652	24292784
ENSE00002541954	24299581	24299780
ENSE00003469620	24290598	24290995
ENSE00003498444	24291139	24291219
ENSE00003526017	24296509	24296588
ENSE00003615563	24296738	24296881
ENSE00003626113	24298957	24299130
ENSE00003641418	24291556	24291625
ENSE00003691794	24292184	24292330

Expression profiles

Bgee: expression breadth ubiquitous, 138 present calls, max score 98.41.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.9688 / max 127.4112, expressed in 1795 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
142583	12.5945	1794
142582	0.3743	147

Top tissues by expression

138 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	98.41	gold quality
esophagus mucosa	UBERON:0002469	97.66	gold quality
right lobe of liver	UBERON:0001114	97.23	gold quality
liver	UBERON:0002107	96.20	gold quality
duodenum	UBERON:0002114	95.95	gold quality
skin of leg	UBERON:0001511	95.64	gold quality
zone of skin	UBERON:0000014	95.46	gold quality
skin of abdomen	UBERON:0001416	95.25	gold quality
mucosa of transverse colon	UBERON:0004991	94.21	gold quality
vagina	UBERON:0000996	93.86	gold quality
esophagus	UBERON:0001043	93.01	gold quality
minor salivary gland	UBERON:0001830	93.00	gold quality
saliva-secreting gland	UBERON:0001044	92.93	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.86	gold quality
small intestine	UBERON:0002108	92.69	gold quality
spleen	UBERON:0002106	92.38	gold quality
transverse colon	UBERON:0001157	92.21	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	91.75	gold quality
ectocervix	UBERON:0012249	91.25	gold quality
left lobe of thyroid gland	UBERON:0001120	91.22	gold quality
metanephros cortex	UBERON:0010533	91.17	gold quality
left adrenal gland	UBERON:0001234	91.14	gold quality
left adrenal gland cortex	UBERON:0035825	91.03	gold quality
right adrenal gland	UBERON:0001233	90.98	gold quality
right adrenal gland cortex	UBERON:0035827	90.98	gold quality
uterine cervix	UBERON:0000002	90.95	gold quality
prostate gland	UBERON:0002367	90.92	gold quality
adult mammalian kidney	UBERON:0000082	90.84	gold quality
thyroid gland	UBERON:0002046	90.83	gold quality
intestine	UBERON:0000160	90.77	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.56
E-CURD-10	no	107.45

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting DHRS1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057

Literature-anchored findings (GeneRIF, showing 5)

• novel human SDR-type dehydrogenase/reductase gene named Dehydrogenase/reductase (SDR family) member 1 (DHRS1) (PMID:12153138)
• Data suggest that members of short chain dehydrogenase/reductase superfamily (human DHRS1; E coli galE) exhibit conserved residues and tertiary structure in active site domain that are essential for biocatalysis. (PMID:25052469)
• DHRS1 was proven to be an NADPH-dependent reductase that is able to catalyse the in vitro reductive conversion of some steroids (estrone, androstene-3,17-dione and cortisone), as well as other endogenous substances and xenobiotics. (PMID:30031147)
• Decreased DHRS1 expression is a novel predictor of poor survival in patients with hepatocellular carcinoma. (PMID:34498498)
• Construction and validation of a immune-related prognostic gene DHRS1 in hepatocellular carcinoma based on bioinformatic analysis. (PMID:37861541)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	dhrs1	ENSDARG00000054300
mus_musculus	Dhrs1	ENSMUSG00000002332
rattus_norvegicus	Dhrs1	ENSRNOG00000020264
drosophila_melanogaster	CG31546	FBGN0051546
drosophila_melanogaster	CG31548	FBGN0051548
caenorhabditis_elegans		WBGENE00000973
caenorhabditis_elegans		WBGENE00019109

Paralogs (13): RDH8 (ENSG00000080511), DHRS7 (ENSG00000100612), DHRS2 (ENSG00000100867), DHRS7B (ENSG00000109016), HSD11B1 (ENSG00000117594), HSDL2 (ENSG00000119471), DHRS4 (ENSG00000157326), CBR1 (ENSG00000159228), CBR3 (ENSG00000159231), HSD11B1L (ENSG00000167733), DHRS7C (ENSG00000184544), DHRS4L2 (ENSG00000187630), DHRS11 (ENSG00000278535)

Protein

Protein identifiers

Dehydrogenase/reductase SDR family member 1 — Q96LJ7 (reviewed: Q96LJ7)

Alternative names: Short chain dehydrogenase/reductase family 19C member 1

All UniProt accessions (2): Q96LJ7, H0YNC2

UniProt curated annotations — full annotation on UniProt →

Function. NADPH-dependent oxidoreductase which catalyzes the reduction of steroids (estrone, androstene-3,17-dione and cortisone) as well as prostaglandin E1, isatin and xenobiotics in vitro. May have a role in steroid and/or xenobiotic metabolism.

Subcellular location. Endoplasmic reticulum.

Tissue specificity. Detected in heart, liver, adrenal glands, and at low levels in skeletal muscle, kidney, pancreas and brain.

Domain organisation. May be attached to the ER membrane by its C-terminus segment.

Similarity. Belongs to the short-chain dehydrogenases/reductases (SDR) family.

RefSeq proteins (2): NP_001129522, NP_612461 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002347	SDR_fam	Family
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily

Pfam: PF00106

Catalyzed reactions (Rhea), 4 shown:

• testosterone + NADP(+) = androst-4-ene-3,17-dione + NADPH + H(+) (RHEA:14981)
• 17alpha-estradiol + NADP(+) = estrone + NADPH + H(+) (RHEA:16705)
• isatin + NADPH + H(+) = 3-hydroxyindolin-2-one + NADP(+) (RHEA:68608)
• prostaglandin E1 + NADPH + H(+) = prostaglandin F1 + NADP(+) (RHEA:68612)

UniProt features (41 total): helix 13, strand 7, binding site 6, turn 5, sequence conflict 3, modified residue 2, initiator methionine 1, chain 1, sequence variant 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2QQ5	X-RAY DIFFRACTION	1.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96LJ7-F1	90.76	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 163 (proton acceptor)

Ligand- & substrate-binding residues (6): 19; 64; 151; 163; 167; 198

Post-translational modifications (2): 2, 21

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 192 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, LUCAS_HNF4A_TARGETS_UP, BILD_SRC_ONCOGENIC_SIGNATURE, chr14q12, GOLDRATH_ANTIGEN_RESPONSE, FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_DN, BROWNE_HCMV_INFECTION_48HR_DN, GOMF_STEROID_DEHYDROGENASE_ACTIVITY_ACTING_ON_THE_CH_OH_GROUP_OF_DONORS_NAD_OR_NADP_AS_ACCEPTOR, CADWELL_ATG16L1_TARGETS_DN, CAIRO_HEPATOBLASTOMA_DN, SANSOM_APC_TARGETS_DN, MODULE_88, MORF_PML

GO Biological Process (1): SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition (GO:0006617)

GO Molecular Function (6): carbonyl reductase (NADPH) activity (GO:0004090), oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616), testosterone dehydrogenase (NADP+) activity (GO:0047045), estradiol 17-alpha-dehydrogenase [NAD(P)+] activity (GO:0047881), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (2): endoplasmic reticulum (GO:0005783), signal recognition particle, endoplasmic reticulum targeting (GO:0005786)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
SRP-dependent cotranslational protein targeting to membrane	1
protein-containing complex assembly	1
alcohol dehydrogenase (NADP+) activity	1
oxidoreductase activity, acting on CH-OH group of donors	1
17-beta-hydroxysteroid dehydrogenase (NADP+) activity	1
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	1
binding	1
catalytic activity	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
signal recognition particle	1

Protein interactions and networks

STRING

2933 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DHRS1	COX18	Q8N8Q8	457
DHRS1	DHRS7B	Q6IAN0	448
DHRS1	DHRS7	Q9Y394	437
DHRS1	TTC38	Q5R3I4	430
DHRS1	RDH10	Q8IZV5	427
DHRS1	RRN3	Q9NYV6	418
DHRS1	DHRS9	Q9BPW9	396
DHRS1	FAR2	Q96K12	379
DHRS1	C1orf226	A1L170	370
DHRS1	ZNF575	Q86XF7	368
DHRS1	PRELID3B	Q9Y3B1	367
DHRS1	RABGGTA	Q92696	359
DHRS1	IYD	Q6PHW0	358
DHRS1	TEN1	Q86WV5	351
DHRS1	ZMAT2	Q96NC0	348

IntAct

104 interactions, top by confidence:

A	B	Type	Score
KRTAP10-8	DHRS1	psi-mi:“MI:0915”(physical association)	0.720
DHRS1	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.720
DHRS1	MDFI	psi-mi:“MI:0915”(physical association)	0.670
MDFI	DHRS1	psi-mi:“MI:0915”(physical association)	0.670
	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
DHRS1	KRTAP5-9	psi-mi:“MI:0915”(physical association)	0.560
DHRS1	NOTCH2NLA	psi-mi:“MI:0915”(physical association)	0.560
DHRS1	KRTAP3-2	psi-mi:“MI:0915”(physical association)	0.560
DHRS1		psi-mi:“MI:0915”(physical association)	0.560
KRTAP5-9	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP3-2	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
NOTCH2NLA	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP12-2	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
MTUS2	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP6-3	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP1-3	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRT34	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
NOTCH2NLC	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP1-1	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP5-1	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP12-3	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP5-2	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP12-1	DHRS1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP6-2	DHRS1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (56): DHRS1 (Two-hybrid), DHRS1 (Two-hybrid), KRTAP10-8 (Two-hybrid), KRTAP10-3 (Two-hybrid), NOTCH2NL (Two-hybrid), DHRS1 (Two-hybrid), DHRS1 (Two-hybrid), DHRS1 (Proximity Label-MS), DHRS1 (Proximity Label-MS), DHRS1 (Two-hybrid), DHRS1 (Two-hybrid), DHRS1 (Two-hybrid), DHRS1 (Two-hybrid), DHRS1 (Two-hybrid), LCE2B (Two-hybrid)

ESM2 similar proteins: A0A0H3KNE7, A0A3Q8GL18, A0A3Q8GLE8, A0A3Q8GYY4, A0A7N9VSG0, A0A7T8F1N2, A0A8F5XX49, A0A8I6GJ95, A0AAT9JA24, A5W4G5, A8C7R7, B8A5W4, D4A2B7, E9Q3D4, E9QUT3, G4N290, O35048, P0C622, P14061, P23102, P37440, P51656, P51661, P9WES5, P9WGQ2, P9WGQ3, Q08632, Q13268, Q17QU7, Q17QW3, Q4WR19, Q5C9I9, Q5R9W5, Q5SS80, Q7FAE1, Q7ZY31, Q8SPU8, Q8VBZ0, Q8XBJ4, Q91WL8

Diamond homologs: A0A097ZPE8, A0A0S2CGD3, A0A144Y7G4, A0A162J3X8, A0A1U8QWA2, A0A1W5SR39, A0A2I1C3V7, A4FUZ6, A6SSW9, A7AZH2, A7IQF2, A7LB60, D3U1D9, G4N290, I6Y778, M1W848, P07772, P08088, P0A2D1, P0A2D2, P0DKC5, P0DKC6, P0DXE1, P13859, P14061, P14802, P15047, P16542, P28643, P31808, P35320, P37440, P42317, P51656, P51657, P52037, P55541, P59837, P66778, P73574

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 39 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	19	34.1×	2e-24

Disease & clinical

Clinical variants and AI predictions

ClinVar

57 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	44
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1453 predictions. Top by Δscore:

Variant	Effect	Δscore
14:24291626:C:CC	acceptor_gain	1.0000
14:24292179:CCAA:C	donor_loss	1.0000
14:24292181:AAC:A	donor_loss	1.0000
14:24292182:ACCT:A	donor_loss	1.0000
14:24292183:C:G	donor_loss	1.0000
14:24292212:T:TA	donor_gain	1.0000
14:24292215:T:TA	donor_gain	1.0000
14:24292327:CACA:C	acceptor_gain	1.0000
14:24292329:CA:C	acceptor_gain	1.0000
14:24292331:C:CC	acceptor_gain	1.0000
14:24296504:CCCA:C	donor_loss	1.0000
14:24296506:CA:C	donor_loss	1.0000
14:24296508:C:CA	donor_loss	1.0000
14:24296585:TCGT:T	acceptor_gain	1.0000
14:24296586:CGT:C	acceptor_gain	1.0000
14:24296586:CGTC:C	acceptor_gain	1.0000
14:24296589:C:CC	acceptor_gain	1.0000
14:24299576:CTTAC:C	donor_loss	1.0000
14:24299577:TTA:T	donor_loss	1.0000
14:24299578:TACCT:T	donor_loss	1.0000
14:24299579:A:T	donor_loss	1.0000
14:24299580:C:A	donor_loss	1.0000
14:24291621:TTGAA:T	acceptor_gain	0.9900
14:24291622:TGAA:T	acceptor_gain	0.9900
14:24292147:C:A	donor_gain	0.9900
14:24292173:C:A	donor_gain	0.9900
14:24292183:CCTG:C	donor_gain	0.9900
14:24292186:G:A	donor_gain	0.9900
14:24292196:AGGAT:A	donor_gain	0.9900
14:24292200:T:TA	donor_gain	0.9900

AlphaMissense

2011 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:24296537:A:G	W116R	0.996
14:24296537:A:T	W116R	0.996
14:24296535:C:A	W116C	0.993
14:24296535:C:G	W116C	0.993
14:24292710:G:A	S150F	0.991
14:24292659:T:A	K167I	0.986
14:24292710:G:T	S150Y	0.985
14:24296559:G:C	F108L	0.983
14:24296559:G:T	F108L	0.983
14:24296561:A:G	F108L	0.983
14:24291584:A:C	S232R	0.982
14:24291584:A:T	S232R	0.982
14:24291586:T:G	S232R	0.982
14:24296536:C:G	W116S	0.981
14:24296759:G:C	N91K	0.981
14:24296759:G:T	N91K	0.981
14:24296763:A:T	V90D	0.980
14:24292759:C:A	G134W	0.978
14:24296558:A:G	W109R	0.977
14:24296558:A:T	W109R	0.977
14:24291582:C:T	G233D	0.975
14:24292653:G:T	A169E	0.975
14:24292758:C:T	G134E	0.975
14:24299048:C:T	G20D	0.975
14:24299055:C:G	G18R	0.975
14:24292245:G:A	T198I	0.974
14:24299006:A:T	V34D	0.974
14:24291582:C:A	G233V	0.973
14:24292264:A:G	W192R	0.973
14:24292264:A:T	W192R	0.973

dbSNP variants (sampled 300 via entrez): RS1000065403 (14:24290706 G>GCACCCCAGAACT), RS1000147165 (14:24297185 G>A), RS1000203991 (14:24299737 T>G), RS1000752062 (14:24291312 C>T), RS1000827936 (14:24299871 C>G,T), RS1000935069 (14:24298441 C>G), RS1001303626 (14:24297784 T>C), RS1001489980 (14:24294225 A>G), RS1001805162 (14:24297466 C>T), RS1002855739 (14:24290524 A>G), RS1003062732 (14:24293350 G>C,T), RS1003398510 (14:24291907 G>A), RS1003534757 (14:24291504 C>A,T), RS1004233335 (14:24296204 T>A), RS1004380258 (14:24299351 A>G)

Disease associations

OMIM: gene MIM:610410 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002371_1	Parent of origin effect on language impairment (paternal)	4.000000e-08

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression, increases expression	3
Valproic Acid	decreases methylation, increases expression, decreases expression	3
Cyclosporine	decreases expression	3
sodium arsenite	decreases expression, increases expression	2
cobaltous chloride	decreases expression	2
Leflunomide	decreases expression	2
aristolochic acid I	increases expression	1
methylmercuric chloride	decreases expression	1
alpha phellandrene	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	affects expression	1
beta-lapachone	decreases expression, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
potassium chromate(VI)	decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
beta-methylcholine	affects expression	1
perfluoro-n-nonanoic acid	decreases expression	1
ICG 001	decreases expression	1
jinfukang	increases expression, affects cotreatment	1
Arsenic Trioxide	affects binding, decreases reaction	1
Benzo(a)pyrene	decreases expression	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, increases expression	1
Curcumin	decreases expression	1
Diazinon	increases methylation	1
Diuron	decreases expression	1
Ivermectin	decreases expression	1
NADP	affects binding, increases activity	1
Thimerosal	decreases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SK77	HAP1 DHRS1 (-) 1	Cancer cell line	Male
CVCL_XN25	HAP1 DHRS1 (-) 2	Cancer cell line	Male
CVCL_XN26	HAP1 DHRS1 (-) 3	Cancer cell line	Male
CVCL_XN27	HAP1 DHRS1 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.